This collection of articles from Bloomberg below is an examination of the recent wave of drug-testing scandals.
They include a look at the case of the patients who experienced potentially deadly reactions during a British drug test last month, and the cover-ups and conflicts of interest that led to the situation.
Other pieces track the progress of a U.S. Senate probe into New Jersey-based SFBC International, a drug-testing company that allowed a Haitian immigrant and tuberculosis patient to participate in a drug trial, infecting other patients as well as company employees.
Another article describes a doctor who volunteered for a drug-testing trial and died as a result of improper monitoring, poor care, and insufficient warnings.
Taken as a whole, the articles paint a dark picture of the current state of drug testing, in terms of the safety of both the final products and the tests themselves.